{"id":22614,"date":"2025-09-24T12:27:22","date_gmt":"2025-09-24T16:27:22","guid":{"rendered":"https:\/\/www.arsacs.com\/?p=22614"},"modified":"2026-03-16T18:18:04","modified_gmt":"2026-03-16T22:18:04","slug":"une-approche-transcriptomique-pour-la-decouverte-de-medicaments-contre-larsacs-dr-nicolas-dupre-2","status":"publish","type":"post","link":"https:\/\/arsacs.com\/fr\/a-transcriptomic-approach-to-drug-discovery-against-arsacs-dr-nicolas-dupre-2\/","title":{"rendered":"\u201c Une approche transcriptomique pour la d\u00e9couverte de m\u00e9dicaments contre l'ARSACS \u201d \u2013 Dr Nicolas Dupr\u00e9"},"content":{"rendered":"

<\/p>\n\n\n\n

Ce projet vise \u00e0 d\u00e9couvrir de nouvelles cibles th\u00e9rapeutiques et des m\u00e9dicaments potentiels pour l'ARSACS en combinant des \u00e9chantillons sanguins de patients avec une technologie de pointe en mati\u00e8re de cellules souches pluripotentes induites (iPS) et l'intelligence artificielle (IA). L'\u00e9quipe analysera les profils d'expression g\u00e9nique dans les \u00e9chantillons sanguins, les iPS issues des patients et les cellules t\u00e9moins g\u00e9n\u00e9tiquement corrig\u00e9es afin d'identifier les m\u00e9canismes pathologiques communs \u00e0 diff\u00e9rentes SACS<\/em> mutations. Gr\u00e2ce \u00e0 la plateforme d'IA RAPTOR d'Oncocross, environ 25 000 candidats-m\u00e9dicaments seront cribl\u00e9s afin d'identifier des compos\u00e9s susceptibles d'inverser les modifications cellulaires associ\u00e9es \u00e0 l'ARSACS.<\/p>\n\n\n\n

Subvention : $25 000<\/p>\n\n\n\n

Dur\u00e9e : un an<\/p>\n\n\n\n

\n
\n
\n
\n
\n
\"\"<\/figure>
\n

Dr Nicolas Dupr\u00e9
LOEX, Aile-R, R-111
H\u00f4pital de l'Enfant-J\u00e9sus
1401, 18e rue
Qu\u00e9bec (Qu\u00e9bec) G1J 1Z4<\/p>\n\n\n\n

Contact :\u00a0\u00a0nicolas.dupre.med@ssss.gouv.qc.ca<\/a><\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

This project aims to discover new therapeutic targets and potential drugs for ARSACS by combining blood samples from patients with advanced iPSC (induced pluripotent stem cell) technology and artificial intelligence (AI). The team will analyze gene expression patterns in blood samples, patient-derived iPSCs, and genetically corrected control cells to identify common disease mechanisms across different SACS mutations. […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-22614","post","type-post","status-publish","format-standard","hentry","category-current"],"_links":{"self":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/22614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/comments?post=22614"}],"version-history":[{"count":6,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/22614\/revisions"}],"predecessor-version":[{"id":25117,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/posts\/22614\/revisions\/25117"}],"wp:attachment":[{"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/media?parent=22614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/categories?post=22614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/arsacs.com\/fr\/wp-json\/wp\/v2\/tags?post=22614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}